This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
This week, we will discuss the final results of the NEFIGARD trial with the GFR slope data. Is targeted release budesonide aka Nefecon really a way to provide steroid efficacy without steroid side effects?
This week, we tag along with NephMadness. It will be hard to stay impartial while discussing the role of angiogenic and antiangiogenic factors in severe preeclampsia prognosis.
This week, during kidney month and NephMadness season, we will discuss the USRDS report as well as the ISN Global Kidney Health Atlas report from 2024.
If you missed this weeks #NephJC chat and want a summary that takes less than 2 minutes to read, check out our second instalment by clicking the link!
Return of #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) January 29, 2022
✳️Rapid #NephJC catch-up✳️
Cochrane & KDIGO recommend children with steroid-sensitive nephrotic syndrome (SSNS) take low dose pred during upper resp tract infection (URTI) to ⬇️relapse risk, based on 4 small studies - does this hold up in a big RCT? pic.twitter.com/yGErtDE9Q6
Since we have two trials, we have two visual abstracts from the IPNA JC team, and NSMC faculty, Md Abdul Qader and S. Sudha Mannemuddhu
In addition, we also have Spanish versions! Thanks to Franklin Loachamin and Juan Kupferman for translating them:
